In this chapter, we present the methodology currently applied in our laboratory for the structural elucidation of the cerebrospinal fluid (CSF) N-glycome. book cover N-glycans are released from denatured carboxymethylated glycoproteins by digestion with peptide-N-glycosidase F (PNGase F) and purified using both C18 Sep-Pak® and porous graphitized carbon (PGC) HyperSepTM HypercarbTM solid-phase extraction (SPE) cartridges. The glycan pool is subsequently permethylated to increase mass spectrometry sensitivity. Molecular assignments are performed through matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF MS) analysis considering either the protein N-inked glycosylation pathway or MALDI TOF MS/MS data. Each stage has been optimized to obtain high-quality mass spectra in reflector mode with an optimal signal-to-noise ratio up to m/z 4800. This method has been successfully adopted to associate specific N-glycome profiles to the early and the advanced phases of Alzheimer's disease.

CSF N-Glycomics Using MALDI MS Techniques in Alzheimer's Disease

Palmigiano Angelo;Messina Angela;Bua Rosaria Ornella;Barone Rita;Garozzo Domenico
2018

Abstract

In this chapter, we present the methodology currently applied in our laboratory for the structural elucidation of the cerebrospinal fluid (CSF) N-glycome. book cover N-glycans are released from denatured carboxymethylated glycoproteins by digestion with peptide-N-glycosidase F (PNGase F) and purified using both C18 Sep-Pak® and porous graphitized carbon (PGC) HyperSepTM HypercarbTM solid-phase extraction (SPE) cartridges. The glycan pool is subsequently permethylated to increase mass spectrometry sensitivity. Molecular assignments are performed through matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF MS) analysis considering either the protein N-inked glycosylation pathway or MALDI TOF MS/MS data. Each stage has been optimized to obtain high-quality mass spectra in reflector mode with an optimal signal-to-noise ratio up to m/z 4800. This method has been successfully adopted to associate specific N-glycome profiles to the early and the advanced phases of Alzheimer's disease.
2018
Istituto per i Polimeri, Compositi e Biomateriali - IPCB
Inglese
Biomarkers for Alzheimer's Disease Drug Development
75
91
17
978-1-4939-7703-1
Humana Press Inc.
Totowa
STATI UNITI D'AMERICA
Sì, ma tipo non specificato
AD
CSF
N-glycans
MALDI MS
MCI
7
02 Contributo in Volume::02.01 Contributo in volume (Capitolo o Saggio)
268
none
Palmigiano, Angelo; Messina, Angela; Bua, Rosaria Ornella; Barone, RITA MARIA ELISA; Sturiale, Luisa; Zappia, Mario; Garozzo, Domenico
info:eu-repo/semantics/bookPart
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/351934
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 15
social impact